Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging the vesicular monoamine transporter.

K A Frey1, R A Koeppe, M R Kilbourn

  • 1Departments of Radiology and Neurology, University of Michigan, Ann Arbor, Michigan 48109-0028, USA.

Advances in Neurology
|September 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biodistribution of 99mTc-MAA on SPECT/CT performed for 90Y radioembolization therapy planning: a pictorial review.

Clinical and translational imaging·2018
Same author

Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease.

Parkinsonism & related disorders·2016
Same author

Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease.

Academic radiology·2016
Same author

It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder.

Molecular psychiatry·2015
Same author

Social feedback activates the endogenous opioid system.

Molecular psychiatry·2013
Same author

Verbal Working Memory Load Affects Regional Brain Activation as Measured by PET.

Journal of cognitive neuroscience·2013

Quantitative measures of vesicular monoamine transporter 2 (VMAT2) binding sites offer a reliable way to assess nigrostriatal integrity in Parkinson's disease models. Positron emission tomography (PET) with (+)11C-DTBZ enables precise VMAT2 measurement for tracking disease progression and evaluating therapies.

Area of Science:

  • Neuroscience
  • Radiochemistry
  • Medical Imaging

Background:

  • Nigrostriatal pathway integrity is crucial for motor function.
  • Assessing this pathway's health is vital for understanding and treating Parkinson's disease (PD).
  • Current methods for evaluating PD progression have limitations.

Purpose of the Study:

  • To evaluate vesicular monoamine transporter 2 (VMAT2) binding sites as a surrogate marker for nigrostriatal projection integrity.
  • To assess the utility of Positron Emission Tomography (PET) with the novel tracer (+)11C-DTBZ for measuring human VMAT2.
  • To establish a method for objective measurement of PD severity and progression.

Main Methods:

  • Utilized quantitative measures of striatal VMAT2 binding sites in experimental animal models.

Related Experiment Videos

  • Employed Positron Emission Tomography (PET) with the novel tracer (+)11C-DTBZ for human VMAT2 measurement.
  • Investigated the effect of dopaminergic drugs and lesion compensatory effects on VMAT2 binding.

    • Main Results:

    • Striatal VMAT2 binding sites serve as an excellent surrogate for nigrostriatal projection integrity in animal models.
    • VMAT2 binding levels were not significantly affected by dopaminergic drugs or lesion compensatory effects.
    • (+)11C-DTBZ PET provides precise and specific measures of human VMAT2.

    Conclusions:

    • Quantitative VMAT2 measurement using PET is a highly suitable method for objectively assessing PD severity and progression.
    • This methodology is essential for future research into disease-modifying therapies for Parkinson's disease.